人血白蛋白对高胆红素血症和低蛋白血症新生儿的临床疗效和安全性评价

发布时间：2018-07-22 19:26

【摘要】：目的评价人血白蛋白对高胆红素血症和低蛋白血症新生儿的临床疗效和安全性。方法采用回顾性调查分析方法,选取2015年6月至2016年5月间收治的高胆红素血症和低蛋白血症新生儿264例资料,将其分为高胆红素血症组64例和低蛋白血症组200例;分别采用人血白蛋白后,分析其治疗前后对TBIL、DBIL、IBIL、白蛋白水平以及心功能各指标的影响。结果高胆红素血症组新生儿治疗前胆红素测得值为(381.2±49.4)μmol/L,给予人血白蛋白日剂量为(3.8±1.5)g,用药疗程为(1.0±0.5)d后,总胆红素水平降至(126.9±26.1)μmol/L;低蛋白血症者组新生儿用药前白蛋白测得值为(23.3g±4.9)g/L,给予人血白蛋白日剂量为(2.6±1.1)g,用药疗程为(1.3±0.7)d后,白蛋白测得值升至(43.3±4.0)g/L。结论采用人血白蛋白治疗高胆红素血症和低蛋白血症新生儿,对改善低白蛋白导致的高胆红素血症和低蛋白血症有着显著的疗效,安全性较好。
[Abstract]:Objective to evaluate the clinical efficacy and safety of human serum albumin (HSA) in neonates with hyperbilirubinemia and hypoproteinemia. Methods from June 2015 to May 2016, 264 neonates with hyperbilirubinemia and hypoproteinemia were randomly divided into hyperbilirubinemia group (n = 64) and hypoproteinemia group (n = 200). The effects of human serum albumin (HSA) on the levels of IBIL, albumin and cardiac function before and after treatment were analyzed. Results in the hyperbilirubinemia group, the bilirubin level was (381.2 卤49.4) 渭 mol / L before treatment, the daily dose of human serum albumin was (3.8 卤1.5) g, and the course of treatment was (1.0 卤0.5) days later. The total bilirubin level decreased to (126.9 卤26.1) 渭 mol / L, and the serum albumin level in hypoproteinemia group was (23.3g 卤4.9) g / L, and the daily dose of human serum albumin was (2.6 卤1.1) g / L, and the albumin level increased to (43.3 卤4.0) g / L after treatment for (1.3 卤0.7) days. Conclusion the treatment of hyperbilirubinemia and hypoproteinemia in neonates with human serum albumin is effective and safe in improving hyperbilirubinemia and hypoproteinemia caused by low albumin.
【作者单位】：南京医科大学附属苏州医院;苏州科技城医院药学部;
【基金】：江苏省药学会百特医院药学科研项目,项目编号为008
【分类号】：R722.1

【相似文献】